Work

Supplementary Tables S1-S3 from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Tables S1-S3 from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies

DOI: 10.1158/1078-0432.22440444

Authors: Deirdre O'Mahony, John C. Morris, Maryalice Stetler-Stevenson, Helen Matthews, Margaret R. Brown, Thomas Fleisher, Stefania Pittaluga, Mark Raffeld, Paul S. Albert, Dirk Reitsma, Karen Kaucic, Luz Hammershaimb, Thomas A. Waldmann, John E. Janik

Language: English

Topic: Viral-associated cancers and disorders

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361880049

Cites:

Cited by:

Related to: 10